SIRT3 and breast carcinoma: Moreover, SIRT3 can inhibit breast carcinoma glycolysis through deacetylation and inactivation of cyclophilin D. This further inhibits the binding of the lactate metabolism enzyme hexokinase II (HK II) to mitochondria to obstruct glycolysis 88.